Research programme: non-small cell lung cancer therapeutics - Benitec

Drug Profile

Research programme: non-small cell lung cancer therapeutics - Benitec

Alternative Names: Tribetarna

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Cancer Institute Australia for Medical Research
  • Developer Benitec Biopharma
  • Class Small interfering RNA
  • Mechanism of Action Beta III tubulin protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Australia (Parenteral)
  • 11 Jan 2015 Research programme: non-small cell lung cancer therapeutics - Benitec is available for licensing as of 11 Jan 2015. http://www.benitec.com
  • 08 Jan 2015 Pharmacodynamics data from a preclinical study in Pancreatic cell cancer released by Benitec Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top